Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors-Reference-Cited by-同舟云学术

Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors

Published:2021-08-25 Issue:608 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Belmontes Brian¹²^ORCID,Sawant Deepali V.¹³^ORCID,Zhong Wendy¹³^ORCID,Tan Hong¹²^ORCID,Kaul Anupurna¹³^ORCID,Aeffner Famke¹⁴^ORCID,O’Brien Sarah A.¹³,Chun Matthew¹³,Noubade Rajkumar¹³^ORCID,Eng Jason¹³,Ma Hayley¹²,Muenz Markus¹⁵,Li Peng¹⁶^ORCID,Alba Benjamin M.¹⁶,Thomas Melissa¹⁶^ORCID,Cook Kevin¹⁷^ORCID,Wang Xiaoting¹⁴^ORCID,DeVoss Jason¹³^ORCID,Egen Jackson G.¹³^ORCID,Nolan-Stevaux Olivier¹³^ORCID

Affiliation:

1. Amgen Research, Thousand Oaks, CA 91320, USA.

2. Inflammation and Oncology Therapeutic Area, Amgen, Thousand Oaks, CA 91320, USA.

3. Inflammation and Oncology Therapeutic Area, Amgen, South San Francisco, CA 94080, USA.

4. Translational Safety and Bioanalytical Sciences, Amgen, South San Francisco, CA 94080, USA.

5. Amgen Research GmbH, Munich 81477, Germany.

6. Therapeutic Discovery, Amgen, South San Francisco, CA 94080, USA.

7. Pharmacokinetics and Drug Metabolism, Amgen, South San Francisco, CA 94080, USA.

Abstract

Immune checkpoint blockade and 4-1BB agonism overcome primary resistance to bispecific T cell engager therapy in T cell–cold solid tumors.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference88 articles.

1. Cancer immunotherapy using checkpoint blockade

2. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

3. Genomic correlates of response to immune checkpoint blockade

4. PD-1 blockade induces responses by inhibiting adaptive immune resistance

5. Tumor Mutational Burden and Response Rate to PD-1 Inhibition

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cascade piezocatalytic nanoprodrug for synergistic piezocatalytic therapy and sono-activated chemotherapy-augmented immunotherapy;Nano Today;2024-10

2. Recent Advancements in Cell-Based Therapies in Melanoma;International Journal of Molecular Sciences;2024-09-12

3. Bispecific T-Cell Engagers (BiTEs) in Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

4. A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia;Leukemia;2024-08-26

5. Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse;Leukemia;2024-08-22